RPRX
Income statement / Annual
Last year (2024), Royalty Pharma plc's total revenue was $2.26 B,
a decrease of 3.85% from the previous year.
In 2024, Royalty Pharma plc's net income was $859.00 M.
See Royalty Pharma plc,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$2.26 B |
$2.35 B |
$2.24 B |
$2.29 B |
$2.12 B |
$1.81 B |
$1.79 B |
$1.60 B |
$1.88 B |
$1.65 B |
Cost of Revenue |
$0.00
|
$560.66 M
|
$5.67 M
|
$23.00 M
|
$88.11 M
|
$1.02 B
|
$135.96 M
|
$33.27 M
|
$0.00
|
$0.00
|
Gross Profit |
$2.26 B
|
$1.79 B
|
$2.23 B
|
$2.27 B
|
$2.03 B
|
$794.93 M
|
$1.66 B
|
$1.56 B
|
$1.88 B
|
$1.65 B
|
Gross Profit Ratio |
1
|
0.76
|
1
|
0.99
|
0.96
|
0.44
|
0.92
|
0.98
|
1
|
1
|
Research and Development Expenses |
$2.00 M
|
$52.00 M
|
$177.11 M
|
$200.08 M
|
$26.00 M
|
$83.04 M
|
$392.61 M
|
$117.87 M
|
$91.02 M
|
$98.38 M
|
General & Administrative Expenses |
$237.00 M
|
$249.75 M
|
$227.30 M
|
$182.83 M
|
$182.00 M
|
$103.44 M
|
$61.91 M
|
$106.44 M
|
$0.00
|
$0.00
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$237.00 M
|
$249.75 M
|
$227.30 M
|
$182.83 M
|
$182.00 M
|
$103.44 M
|
$61.91 M
|
$106.44 M
|
$69.51 M
|
$121.42 M
|
Other Expenses |
$732.00 M
|
$0.00
|
$909.91 M
|
$475.84 M
|
$319.00 M
|
-$995.40 M
|
-$1.52 M
|
-$1.62 M
|
-$925.80 M
|
-$570.18 M
|
Operating Expenses |
$971.00 M
|
$862.40 M
|
$1.31 B
|
$858.75 M
|
$527.00 M
|
-$808.92 M
|
$430.45 M
|
$658.24 M
|
$1.09 B
|
$789.98 M
|
Cost And Expenses |
$972.00 M
|
$862.40 M
|
$1.31 B
|
$858.75 M
|
$527.00 M
|
-$808.92 M
|
$430.45 M
|
$658.24 M
|
$1.15 B
|
$858.14 M
|
Interest Income |
$0.00
|
$72.29 M
|
$78.34 M
|
$53.54 M
|
$28.38 M
|
$22.33 M
|
$24.44 M
|
$6.76 M
|
$0.00
|
$0.00
|
Interest Expense |
$226.00 M
|
$187.19 M
|
$187.96 M
|
$166.14 M
|
$157.00 M
|
$268.57 M
|
$279.96 M
|
$247.34 M
|
$238.92 M
|
$224.42 M
|
Depreciation & Amortization |
$0.00
|
$395.13 M
|
$5.67 M
|
$23.00 M
|
$23.06 M
|
$23.92 M
|
$33.27 M
|
$33.27 M
|
$68.20 M
|
$68.16 M
|
EBITDA |
$1.29 B |
$1.89 B |
$928.56 M |
$1.45 B |
$1.68 B |
$2.65 B |
$1.40 B |
$972.96 M |
$1.07 B |
$862.44 M |
EBITDA Ratio |
0.57
|
0.8
|
0.44
|
0.65
|
0.89
|
1.45
|
0.79
|
0.71
|
0.42
|
0.52
|
Operating Income Ratio |
0.57
|
0.63
|
0.44
|
0.62
|
0.75
|
1.45
|
0.76
|
0.59
|
0.39
|
0.48
|
Total Other Income/Expenses Net |
$39.00 M
|
$207.94 M
|
-$77.00 M
|
-$189.51 M
|
$106.56 M
|
-$161.76 M
|
$153.41 M
|
$403.49 M
|
$39.02 M
|
-$35.57 M
|
Income Before Tax |
$1.33 B
|
$1.70 B
|
$230.06 M
|
$1.24 B
|
$1.70 B
|
$2.46 B
|
$1.52 B
|
$1.34 B
|
$761.90 M
|
$758.71 M
|
Income Before Tax Ratio |
0.59
|
0.72
|
0.1
|
0.54
|
0.8
|
1.36
|
0.85
|
0.84
|
0.41
|
0.46
|
Income Tax Expense |
$472.00 M
|
$0.00
|
$187.23 M
|
$762.45 M
|
$1.15 B
|
$349.33 M
|
$433.37 M
|
$542.66 M
|
$195.99 M
|
$177.28 M
|
Net Income |
$859.00 M
|
$1.13 B
|
$42.83 M
|
$478.75 M
|
$495.20 M
|
$2.35 B
|
$1.38 B
|
$1.21 B
|
$565.91 M
|
$581.43 M
|
Net Income Ratio |
0.38
|
0.48
|
0.02
|
0.21
|
0.23
|
1.29
|
0.77
|
0.76
|
0.3
|
0.35
|
EPS |
1.92 |
3.41 |
0.0978 |
1.15 |
1.32 |
6.42 |
3.89 |
3.42 |
0.93 |
0.96 |
EPS Diluted |
1.45 |
2.53 |
0.0978 |
1.15 |
1.32 |
6.42 |
3.89 |
3.42 |
0.93 |
0.96 |
Weighted Average Shares Out |
$447.63 M
|
$447.60 M
|
$437.96 M
|
$414.79 M
|
$375.44 M
|
$365.90 M
|
$354.18 M
|
$354.18 M
|
$607.04 M
|
$607.04 M
|
Weighted Average Shares Out Diluted |
$592.73 M
|
$602.90 M
|
$437.97 M
|
$607.17 M
|
$375.46 M
|
$365.90 M
|
$354.18 M
|
$354.18 M
|
$607.04 M
|
$607.04 M
|
Link |
|
|
|
|
|
|
|
|
|
|